👦 Childhood Myopia Progression Tracking Simulator

Recording Baseline Refraction at Diagnosis

Placeholder: first exam sets the reference point for tracking.

• 6–9 yrs: Typical onset age (placeholder summary)
• -1.00 D: Baseline refraction (placeholder summary)
• strong: Axial length link (placeholder summary)
• 2-3x: Family history risk (placeholder summary)

Why baseline measurement matters

Placeholder line explaining baseline cycloplegic refraction importance.

Modeling the Untreated Progression Curve

Placeholder: unmanaged myopia progresses fastest in early years.

• -0.75 D/yr: Untreated rate (placeholder summary)
• 8–12 yrs: Peak progression age (placeholder summary)
• elevated: High myopia risk (placeholder summary)
• higher: Retinal risk later (placeholder summary)

Natural history without intervention

Placeholder line describing untreated childhood myopia trajectory.

Glasses-Only Correction Compared to Active Control

Placeholder: glasses correct vision but barely slow progression.

• -0.65 D/yr: Glasses-only rate (placeholder summary)
• ~13%: Slowing vs untreated (placeholder summary)
• yes: Active methods needed (placeholder summary)
• emerging: Myopic defocus lenses (placeholder summary)

Limits of single-vision correction

Placeholder line noting why glasses alone underperform.

Comparative Efficacy of Atropine and Orthokeratology

Placeholder: both methods cut progression roughly in half.

• -0.30 D/yr: Atropine rate (placeholder summary)
• -0.35 D/yr: Ortho-K rate (placeholder summary)
• ~60%: Atropine efficacy (placeholder summary)
• ~53%: Ortho-K efficacy (placeholder summary)

Choosing between active methods

Placeholder line comparing compliance and side-effect tradeoffs.

Targeting Long-Term Refraction Stabilization

Placeholder: goal is a flat curve by late teens.

• ~16-18 yrs: Typical stabilization age (placeholder summary)
• as low as possible: Target final refraction (placeholder summary)
• annual: Continued monitoring (placeholder summary)
• reduced: Adult onset risk (placeholder summary)

Sustaining control into adolescence

Placeholder line on maintaining treatment until stabilization.